594 studies found for:    Open Studies | "Leukemia, Lymphoid"
Show Display Options
Rank Status Study
21 Recruiting Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma
Conditions: Relapsed Lymphoblastic Leukemia;   Recurrent Adult Lymphoblastic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Lymphoblastic Lymphoma
Intervention: Drug: Sirolimus
22 Unknown  High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
Condition: Lymphoblastic Leukemia, Acute
Interventions: Drug: Cyclophosphamide;   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Prednisolone;   Drug: L-asparaginase;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Mercaptopurine;   Drug: Doxorubicin
23 Unknown  Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Condition: Lymphoblastic Leukemia, Acute
Interventions: Drug: Methotrexate;   Drug: Prednisolone;   Drug: Dexamethasone;   Drug: Vincristine;   Drug: Pirarubicin;   Drug: Cyclophosphamide;   Drug: L-asparaginase;   Drug: Cytarabine;   Drug: Hydrocortisone;   Drug: Mercaptopurine
24 Recruiting Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Vincristine Sulfate
25 Recruiting Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Conditions: Leukemia;   Acute Lymphocytic Leukemia
Interventions: Drug: Blinatumomab;   Behavioral: Phone Calls
26 Recruiting Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Adult Lymphoblastic Lymphoma
Interventions: Drug: DNR;   Drug: VCR;   Drug: PEG-asp;   Drug: CTX;   Drug: Prednisone;   Drug: Liposomal AraC;   Drug: MTX;   Drug: LCV;   Drug: AraC;   Drug: Etoposide;   Drug: Dasatinib;   Drug: Rituximab;   Drug: Hydrocortisone
27 Recruiting ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: PEG Asparaginase at six weeks interval;   Drug: PEG Asparaginase at two weeks interval
28 Recruiting Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis
29 Recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Blinatumomab;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Drug: Vincristine Sulfate
30 Unknown  Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology
Condition: Acute Lymphocytic Leukemia
Intervention: Other: Database
31 Unknown  Genomic Changes in Childhood Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
32 Recruiting Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Vincristine;   Drug: Daunorubicin;   Drug: Prednisone;   Drug: Mitoxantrone;   Drug: Cytosine Arabinoside;   Drug: Dexamethasone;   Drug: Methotrexate (MTX);   Drug: Cytarabine;   Drug: ASP;   Drug: Mercaptopurine;   Drug: Teniposide;   Drug: Hydrocortisone
33 Recruiting Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: lenalidomide;   Other: Correlative Studies
34 Recruiting Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Leukemia
Intervention: Drug: pyrimethamine
35 Unknown  My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia
Condition: Lymphoid Leukemia
Intervention: Drug: doxorubicin liposomal
36 Unknown  Osteonecrosis in Children With Acute Lymphoblastic Leukemia
Conditions: Osteonecrosis;   Acute Lymphoblastic Leukemia
37 Recruiting Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)
Conditions: Leukemia;   Acute Lymphoblastic Leukemia
Interventions: Drug: Inotuzumab Ozogamycin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Ara-C
38 Recruiting CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Interventions: Genetic: donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta;   Biological: Irradiated donor-derived Lymphoblastoid Cell Line
39 Recruiting Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Bcl-2 Inhibitor GDC-0199;   Biological: Obinutuzumab;   Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
40 Unknown  Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia
Condition: Acute Lymphocytic Leukemia
Intervention: Drug: Liposomal Annamycin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years